Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice

2026-01-22
CONCORD, Calif., January 22, 2026--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat

3 Promising Penny Stocks With Market Caps Over $100M

2026-01-13
As the S&P 500 and Dow Jones Industrial Average reach new highs, investors are looking beyond the headlines to explore diverse investment opportunities. Penny stocks, though often overlooked in favor of larger market players, continue to offer unique prospects for those willing to navigate this niche. These smaller or newer companies can present a blend of value and growth potential, particularly when supported by strong financial health, making them intriguing options for investors seeking...

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

2026-01-11
CONCORD, Calif., January 11, 2026--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026.

TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS)

2025-12-27
Cerus Corporation (NASDAQ:CERS) is among the Best Get Rich Fast Stocks to Buy Right Now. On December 23, TheFly reported that TD Cowen views Cerus Corporation (NASDAQ:CERS)’s Intercept Fibrinogen Complex franchise as an “underappreciated” growth engine in the long haul. The firm believes the newly announced BCA partnership will significantly enhance its adoption, scalability, and […]

Tracking Baker Brothers Portfolio - Q3 2025 Update

2025-12-16
Discover Baker Brothers' Q3 2025 portfolio shifts—see top biotech stock picks, strategic increases, and key holdings.

Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America

2025-12-10
CONCORD, Calif., December 10, 2025--Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus’ entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for pla

Promising Penny Stocks To Watch In December 2025

2025-12-09
As the Federal Reserve's meeting unfolds, investors are closely monitoring potential interest rate cuts that could influence market dynamics. Amid these developments, penny stocks continue to capture attention as a viable investment area, despite their seemingly outdated label. These smaller or newer companies can offer unique opportunities for growth and value, especially when they demonstrate strong financial resilience.

Cerus: IFC Growth And RBC Optionality

2025-11-23
Discover why CERS is a strong buy as it innovates blood transfusion safety with Intercept technology and eyes near-term positive cash flow.

3 Promising Penny Stocks With Market Caps Under $400M

2025-11-10
As the U.S. stock market grapples with recent volatility, highlighted by the Nasdaq's worst week since 'Liberation Day,' investors are increasingly seeking opportunities beyond traditional large-cap stocks. Penny stocks, despite their somewhat outdated moniker, still hold relevance as they often represent smaller or newer companies that can offer significant growth potential at lower price points. By focusing on those with strong financials and clear growth prospects, investors may uncover...

Cerus Corp (CERS) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Shifts Amid ...

2025-11-07
Cerus Corp (CERS) reports a 15% revenue increase and strategic transitions, despite facing margin pressures and regulatory delays.